Go Pro

Ocular Therapeutix (OCUL) Short Interest Ratio & Short Volume

Ocular Therapeutix logo
$11.08 -0.01 (-0.09%)
As of 08/21/2026 04:00 PM Eastern

Ocular Therapeutix Short Interest Overview

As of July 31, 2026, Ocular Therapeutix (OCUL) had a short interest of 26.74 million shares sold short, representing 12.56% of the public float. This marks a -1.08% decrease in short interest since the prior report. The short interest ratio (days to cover) is 13.5, meaning it would take 13.5 days of the average trading volume of 2.82 million shares to cover all short positions.

Current Short Interest
26,735,397 shares
Previous Short Interest
27,027,521 shares
Change Vs. Previous Month
-1.08%
Dollar Volume Sold Short
$218.43 million
Short Interest Ratio
13.5 Days to Cover
Last Record Date
July 31, 2026
Outstanding Shares
219,620,000 shares
Short Percent of Float
12.56%
Today's Trading Volume
3,051,276 shares
Average Trading Volume
2,823,059 shares
Today's Volume Vs. Average
108%
Short Selling Ocular Therapeutix?
A Guide To High-Short-Interest Stocks

Sign up to receive the latest short interest report for Ocular Therapeutix and its competitors with MarketBeat's FREE newsletter.

Get Report
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.
Skip Charts & View Short Interest History

OCUL Short Interest Over Time

OCUL Days to Cover Over Time

OCUL Percentage of Float Shorted Over Time

Ocular Therapeutix Tesla Short Interest History & Recent Changes

Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
7/31/202626,735,397 shares $218.43 million -1.1%12.6%13.49 $8.17
7/15/202627,027,521 shares $269.19 million +1.3%12.7%13.07 $9.96
6/30/202626,695,136 shares $262.15 million +0.9%12.6%6.56 $9.82
6/15/202626,456,015 shares $237.84 million +5.5%12.5%11.85 $8.99
5/29/202625,086,045 shares $226.03 million +1.2%11.7%9.04 $9.01
5/15/202624,777,685 shares $226.96 million -0.1%11.6%8.49 $9.16
4/30/202624,793,045 shares $232.31 million +1.1%11.6%8.57 $9.37
4/15/202624,526,963 shares $218.54 million -2.6%11.6%6.99 $8.91
3/31/202625,192,853 shares $213.38 million +6.4%11.9%7.2 $8.47
3/13/202623,683,101 shares $207.46 million +34.2%11.1%3.56 $8.76
2/27/202617,648,381 shares $157.78 million +20.0%8.3%1.44 $8.94
2/13/202614,706,215 shares $130.59 million +27.8%6.9%2.98 $8.88
1/30/202611,506,830 shares $105.17 million -10.0%5.4%2.7 $9.14
1/15/202612,790,655 shares $144.28 million +3.6%6.1%2.21 $11.28
12/31/202512,345,939 shares $149.88 million +16.5%5.9%4.32 $12.14
12/15/202510,593,646 shares $150.11 million -8.9%5.1%2.33 $14.17
11/28/202511,633,800 shares $140.56 million -11.7%5.6%3.8 $12.08
11/14/202513,173,573 shares $148.86 million -4.4%7.7%6.89 $11.30
10/31/202513,773,939 shares $160.60 million +1.4%8.1%6.46 $11.66
10/15/202513,590,000 shares $162.26 million +0.2%8.0%5 $11.94
9/30/202513,560,000 shares $158.52 million -11.3%N/A5.2 $11.69
9/15/202515,280,000 shares $191.61 million +10.4%N/A6.6 $12.54
8/31/202513,840,000 shares $168.99 million +5.8%8.1%5.6 $12.21
8/15/202513,080,000 shares $165.07 million +2.0%N/A5.6 $12.62
7/31/202512,830,000 shares $148.57 million -13.3%7.5%5.6 $11.58
7/15/202514,800,000 shares $164.13 million +4.5%N/A6.8 $11.09
6/30/202514,170,000 shares $131.50 million -1.7%9.1%6.5 $9.28
6/15/202514,420,000 shares $125.89 million +1.1%9.3%7.1 $8.73
5/31/202514,260,000 shares $114.22 million +3.1%9.4%7.9 $8.01
5/15/202513,830,000 shares $99.16 million +6.6%9.1%8.2 $7.17
4/30/202512,980,000 shares $107.73 million -7.9%N/A8.2 $8.30
4/15/202514,100,000 shares $106.17 million +12.0%9.3%9.5 $7.53
3/31/202512,590,000 shares $92.28 million -1.9%8.3%9.1 $7.33
3/15/202512,830,000 shares $99.05 million +6.5%8.5%11 $7.72
2/28/202512,050,000 shares $86.04 million +3.9%7.9%11.6 $7.14
2/15/202511,600,000 shares $84.45 million +6.7%7.6%12.8 $7.28
1/31/202510,870,000 shares $83.70 million -2.6%N/A11.8 $7.70
1/15/202511,160,000 shares $90.73 million +3.9%N/A12.5 $8.13
12/31/202410,740,000 shares $91.72 million +2.6%N/A10.5 $8.54
12/15/202410,470,000 shares $90.98 million -1.8%N/A9.6 $8.69
They didn't warn anyone in 1971. This time someone is warning you. (Ad)

On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free.tc pixel

Request the free guide in 30 seconds and get positioned now
11/30/202410,660,000 shares $105.43 million -1.1%N/A9.2 $9.89
11/15/202410,780,000 shares $98.74 million -14.9%N/A9.5 $9.16
10/31/202412,670,000 shares $133.42 million -4.5%N/A11.6 $10.53
10/15/202413,260,000 shares $135.65 million -18.1%N/A11.4 $10.23
9/30/202416,190,000 shares $140.85 million -7.3%N/A13.7 $8.70
9/15/202417,460,000 shares $157.14 million -4.9%N/A12.1 $9.00
8/31/202418,350,000 shares $161.85 million -2.2%N/A11.2 $8.82
8/15/202418,770,000 shares $157.10 million -1.7%N/A10.3 $8.37
7/31/202419,090,000 shares $161.50 million -6.3%N/A9.3 $8.46
7/15/202420,380,000 shares $171.80 million -4.5%N/A8.2 $8.43
6/30/202421,340,000 shares $145.97 million -8.7%N/A8.1 $6.84
6/15/202423,370,000 shares $134.38 million +4.0%N/A9.4 $5.75
5/31/202422,470,000 shares $128.08 million +5.9%N/A9.2 $5.70
5/15/202421,220,000 shares $133.47 million +0.7%N/A8.3 $6.29
4/30/202421,080,000 shares $99.92 million +43.9%N/A7.8 $4.74
4/15/202414,650,000 shares $114.27 million +24.1%N/A6.3 $7.80
3/31/202411,810,000 shares $107.47 million +28.9%N/A5.8 $9.10
3/15/20249,160,000 shares $86.65 million +93.3%N/A4.5 $9.46
2/29/20244,740,000 shares $47.68 million +19.4%N/A2.4 $10.06
2/15/20243,970,000 shares $27.23 million +0.3%N/A2.3 $6.86
1/31/20243,960,000 shares $19.25 million +18.2%N/A2.9 $4.86
1/15/20243,350,000 shares $14.71 million -23.5%N/A2.5 $4.39
12/31/20234,380,000 shares $19.53 million -3.5%N/A3.6 $4.46
12/15/20234,540,000 shares $17.84 million -14.0%N/A3.9 $3.93
11/30/20235,280,000 shares $13.09 million -9.1%7.0%5.9 $2.48
11/15/20235,810,000 shares $13.07 million +22.1%7.7%7.5 $2.25
10/31/20234,760,000 shares $13.57 million +9.4%6.3%6 $2.85
10/15/20234,350,000 shares $10.83 million +6.4%5.8%6.2 $2.49
9/30/20234,090,000 shares $12.84 million -1.7%5.4%5.7 $3.14
9/15/20234,160,000 shares $14.48 million +1.2%5.5%5.2 $3.48
8/31/20234,110,000 shares $15.54 million -16.5%5.5%3.8 $3.78
8/15/20234,920,000 shares $22.19 million -20.3%6.5%4.1 $4.51
7/31/20236,170,000 shares $28.01 million -8.2%N/A5.1 $4.54
7/15/20236,720,000 shares $32.05 million -1.2%N/A5.2 $4.77
6/30/20236,800,000 shares $35.09 million +4.3%N/A5.4 $5.16
6/15/20236,520,000 shares $32.40 million -2.0%N/A5.2 $4.97
5/31/20236,650,000 shares $42.56 million +20.3%N/A6.8 $6.40
5/15/20235,530,000 shares $35.00 million +14.3%N/A5.4 $6.33
4/30/20234,840,000 shares $30.01 million +13.4%N/A3.1 $6.20
4/15/20234,270,000 shares $22.46 million -7.2%N/A2.8 $5.26
3/31/20234,600,000 shares $24.24 million +2.7%N/A3.2 $5.27
3/15/20234,480,000 shares $22.85 million +12.6%N/A3.1 $5.10
2/28/20233,980,000 shares $24.04 million +27.2%N/A2.9 $6.04
2/15/20233,130,000 shares $19.06 million +6.5%4.1%2.4 $6.09
1/31/20232,940,000 shares $11.50 million +4.3%3.9%4.6 $3.91
1/15/20232,820,000 shares $11.28 million -5.1%N/A4.3 $4.00
12/30/20222,970,000 shares $8.35 million -2.3%N/A4.5 $2.81
12/15/20223,040,000 shares $8.42 million +4.1%N/A3.5 $2.77
11/30/20222,920,000 shares $8.67 million -0.3%N/A3.5 $2.97
11/15/20222,930,000 shares $9.43 million -12.0%N/A3.4 $3.22
Trump Takes Emergency Action - Plus Elon Musk's New Venture (Ad)

Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Trump has issued emergency support to accelerate the rollout, and it's already live in multiple states. The Financial Times reports Sam Altman is personally calling people to build this for OpenAI. A few little-known companies control the entire supply chain - meaning anyone who wants access must go through them. Their stocks are available to buy right now.tc pixel

See which companies control the supply chain behind this emerging tech
10/31/20223,330,000 shares $12.02 million +2.2%N/A3.8 $3.61
10/15/20223,260,000 shares $13.43 million +9.4%N/A3.9 $4.12
9/30/20222,980,000 shares $12.37 million +2.4%N/A3.8 $4.15
9/15/20222,910,000 shares $18.07 million -12.1%N/A5.4 $6.21
8/31/20223,310,000 shares $16.81 million -1.5%N/A6.1 $5.08
8/15/20223,360,000 shares $18.48 million -2.3%N/A6.1 $5.50
7/31/20223,440,000 shares $15.41 million -1.4%4.5%5.7 $4.48
7/15/20223,490,000 shares $15.11 million +3.3%4.6%5.5 $4.33
6/30/20223,380,000 shares $13.59 million -3.7%4.4%5 $4.02
6/15/20223,510,000 shares $12.46 million -11.1%4.6%5 $3.55
5/31/20223,950,000 shares $12.36 million +1.0%5.2%5.9 $3.13
5/15/20223,910,000 shares $12.82 million -2.5%5.1%5.8 $3.28
4/30/20224,010,000 shares $14.32 million -0.3%5.3%6.5 $3.57
4/15/20224,020,000 shares $17.61 million -4.1%5.3%6.5 $4.38
3/31/20224,190,000 shares $20.74 million -9.7%5.5%7.2 $4.95
3/15/20224,640,000 shares $23.76 million -0.6%6.1%7.6 $5.12
2/28/20224,670,000 shares $26.06 million +20.4%6.1%7 $5.58
2/15/20223,880,000 shares $21.65 million +15.8%5.1%5.6 $5.58
1/31/20223,350,000 shares $18.96 million +5.4%4.4%4.4 $5.66
1/15/20223,180,000 shares $19.72 million -0.9%4.2%3.6 $6.20
12/31/20213,210,000 shares $22.37 million -4.5%4.2%2.8 $6.97
12/15/20213,360,000 shares $22.38 million +3.7%4.4%2.9 $6.66
11/30/20213,240,000 shares $22.16 million -13.8%4.3%2.8 $6.84
11/15/20213,760,000 shares $26.62 million -6.7%4.9%3.3 $7.08
10/29/20214,030,000 shares $26.76 million -14.6%5.3%3.7 $6.64
10/15/20214,720,000 shares $52.82 million -9.4%6.2%4.6 $11.19
9/30/20215,210,000 shares $52.10 million -10.6%6.8%6.2 $10.00
9/15/20215,830,000 shares $60.05 million +3.0%7.6%7.6 $10.30
8/31/20215,660,000 shares $59.77 million -1.4%7.4%7.4 $10.56

OCUL Short Interest - Frequently Asked Questions

Short interest is the volume of Ocular Therapeutix shares that have been sold short but have not yet been covered or closed out. As of July 31st, traders have sold 26,735,397 shares of OCUL short. 12.56% of Ocular Therapeutix's shares are currently sold short. Learn More on Ocular Therapeutix's current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. OCUL shares currently have a short interest ratio of 13.5. Learn More on Ocular Therapeutix's short interest ratio.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 12.56% of Ocular Therapeutix's floating shares are currently sold short.

Ocular Therapeutix saw a decline in short interest in July. As of July 31st, there was short interest totaling 26,735,397 shares, a decline of 1.1% from the previous total of 27,027,521 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

12.56% of Ocular Therapeutix's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceuticals" compare to Ocular Therapeutix: Liquidia Corporation (18.08%), Lantheus Holdings, Inc. (9.83%), Belite Bio, Inc. Sponsored ADR (3.26%), Amneal Pharmaceuticals, Inc. (3.15%), Definium Therapeutics, Inc. (11.04%), Veradermics, Incorporated (11.54%), Indivior PLC (9.29%), Catalyst Pharmaceuticals, Inc. (0.31%), Structure Therapeutics Inc. Sponsored ADR (9.01%), Organon & Co. (6.51%),

As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($70.50 billion), Invesco QQQ ($50.36 billion), iShares Russell 2000 ETF ($21.20 billion), Western Digital Corporation ($13.40 billion), SPDR S&P Biotech ETF ($11.59 billion), Nebius Group N.V. ($11.46 billion), iShares 20+ Year Treasury Bond ETF ($7.84 billion), iShares iBoxx $ High Yield Corporate Bond ETF ($7.51 billion), iShares Semiconductor ETF ($6.37 billion), and Financial Select Sector SPDR Fund ($6.34 billion). View all of the most shorted stocks.

Short selling OCUL is an investing strategy that aims to generate trading profit from Ocular Therapeutix as its price is falling. OCUL shares are trading down $0.01 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Ocular Therapeutix occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of OCUL, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including OCUL, twice per month. The most recent reporting period available is July, 31 2026.

Understanding short interest metrics can help you assess how traders are positioning around a stock like OCUL:

  • Shares Sold Short: The total number of shares that have been sold by short sellers but have not yet been covered or closed out. A high number may indicate bearish sentiment.
  • Short Float: The percentage of a company’s publicly available shares (or "float") that are sold short. A higher short float suggests a greater portion of the stock is being bet against.
  • Days to Cover (Short Interest Ratio): This estimates how many days it would take short sellers to cover their positions, based on average daily trading volume. Higher values can signal potential for a short squeeze if buying pressure increases.

These metrics are often used by traders to gauge sentiment, volatility risk, and the potential for price movements based on short covering activity.



Short interest data for NASDAQ:OCUL is sourced from the Financial Industry Regulatory Authority (FINRA), with the most recent report published on 8/11/2026. FINRA publishes updated short interest twice a month.
From Our Partners